Biocartis Group NV: Disclosure of a transparency notification


Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today in accordance with Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading (the 'Belgian Transparency Act'), that it received a transparency notification dated 4 January 2018 (the 'Notification'), indicating that the shareholding of the Flemish Region (through PMV-Tina Comm.VA and ParticipatieMaatschappij Vlaanderen NV) has decreased below the 5% notification threshold. It concerns a passive downward crossing of the 5% notification threshold.

The Notification contains the following information:

  • Reason for the Notification: Passive crossing of a threshold.
  • Notification by: A parent undertaking or a controlling person.
  • Persons subject to the notification requirement: PMV-TINA Comm. VA, Oude Graanmarkt 63, 1000 Brussels (Belgium); ParticipatieMaatschappij Vlaanderen NV, Oude Graanmarkt 63, 1000 Brussels (Belgium); Het Vlaamse Gewest (the Flemish Region), Martelaarsplein 19, 1000 Brussels (Belgium).
  • Transaction date: 28 November 2017.
  • Threshold that is crossed: 5%.
  • Denominator: 51,069,772.
  • Details of the Notification: PMV-TINA Comm. VA holds 1,840,861 voting rights and ParticipatieMaatschappij Vlaanderen NV holds 428,000 voting rights.
  • Chain of controlled undertakings through which the holding is effectively being held: Het Vlaamse Gewest (the Flemish Region) controls ParticipatieMaatschappij Vlaanderen NV. ParticipatieMaatschappij Vlaanderen NV owns 100% of the shares of PMV-TINA Comm. VA and as such controls PMV-TINA Comm. VA.

The Notification is available here on the website of the Company.


Pursuant to the Belgian Transparency Act and the articles of association of the Company, a notification to the Company and the Belgian Financial Services and Markets Authority ('FSMA') is required by all natural and legal persons in each case where the percentage of voting rights in the Company held by such persons reaches, exceeds or falls below the threshold of 3%, 5%, 10%, and every subsequent multiple of 5%, of the total number of voting rights in the Company.


Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla(TM) platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis launched the Idylla(TM) platform in September 2014. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide. Today, Biocartis offers twelve oncology tests and two infectious disease tests in Europe. More information: Press Photo Library available here. Follow us on Twitter: @Biocartis_.



Interested in a regular update of the Life Sciences and biotech sector in Flanders?